ScreenerHero

HUMAHumacyte Inc. Common Stock

NAS · US · Healthcare · Biotechnology · humacyte.com
0.6422USD-12.61%Mkt Cap: 178.40M $P/E: —

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of ana…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap178.40M $
Enterprise Value176.27M $
Revenue (TTM)2.12M $
Gross Profit-7.66M $
Net Income (TTM)-40.83M $
Revenue/Share0.0110 USD
Last Price0.6422 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees184
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.75
PEG—
EV/EBITDA-1.71
EV/Revenue83.11
P/S89.25
P/B13.10
EPS (TTM)-0.48
EPS (Forward)-0.25
52W Range
0.52616% of range2.550
52W High2.550 USD
52W Low0.5261 USD
Profitability
Gross Margin-376.05%
Oper. Margin-6649.26%
EBITDA Margin0.00%
Profit Margin-2003.58%
ROE-1313.38%
ROA-35.09%
Growth
Revenue Growth34.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-105.04M $
CapEx (TTM)884.00K $
FCF Margin-2753.10%
FCF Yield-32.73%
Net Debt-13.02M $
Net Debt/EBITDA0.13
Balance Sheet
Debt/Equity20.86
Current Ratio6.21
Quick Ratio5.37
Book Value/Sh0.0520 USD
Cash/Share0.2880 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.850 USD
Upside (mean)+188.1%
Target Range1.000 USD – 4.000 USD
$1.000+188.1% to mean$4.000
# Analysts5
Ownership
Shares Out.277.80M
Float246.35M
Insiders5.60%
Institutions26.61%
Short Interest
Short Ratio4.3d
Short % Float11.75%
Short % Out.11.68%
Shares Short31.49M
Short (prev mo.)31.60M
Technical
SMA 500.7391 (-13.1%)
SMA 2000.9775 (-34.3%)
Beta2.47
S&P 52W Chg18.16%
Avg Vol (30d)7.85M
Avg Vol (10d)13.70M
Technical Indicators
RSI (14)46.5
MACD-0.0292
MACD Signal-0.0335
MACD Hist.+0.0043
BB Upper0.7754 USD
BB Middle0.6644 USD
BB Lower0.5533 USD
BB Width33.43%
ATR (14)0.0772 USD
Vol Ratio (20d)1.17x